RNA sequencing provides valuable insights into gene expression alterations in response to drug treatments, mutations, and gene fusions. Combined analyses of RNA transcript variations and comprehensive genomic sequencing allows for cross-validation of somatic mutations, improvement of accuracy and clinical sensitivity, and understanding of mutation effects on gene expression, yielding essential transcriptomic/genomic data that inform individual patient’s responses to therapeutic interventions.
Here, we employed the novel integrated target capture technology, Trinity™, to simultaneously capture both RNA and DNA libraries in a single hybridization reaction. This optimized workflow significantly decreases sample-to-answer time below 21 hours, with 1 hour hybridization time and direct loading onto sequencing instrument. The assay showed ~ 10% higher mean target coverage at equivalent read depths compared to data generated from the same samples processed using conventional target capture workflow. In summary, using Trinity™ for a combined DNA/RNA hybrid capture workflow led to a rapid, cost-effective workflow to simultaneously unlock both DNA and RNA biomarker insights.